DOI-10-1056-NEJMoa2511774 — ATTAIN-1: Orforglipron in Obesity (Phase 3)

[DRAFT — authored 2026-04-18. Requires Medical Director review.]

Citation

Wharton S, Aroda VR, Ard JD, Blüher M, Garvey WT, Hesse D, Jastreboff AM, Kahn SE, Linneberg A, Lingvay I, Rubino DM, Tatulashvili N, le Roux CW, on behalf of the ATTAIN-1 Trial Investigators. Orforglipron, an Oral Nonpeptide GLP-1 Receptor Agonist, for Obesity (ATTAIN-1). N Engl J Med. 2025;393(19):1889-1901. doi: 10.1056/NEJMoa2511774.

External URL: NEJM DOI resolver

Study Design

Phase: 3
Design: Multicenter, randomized, double-blind, placebo-controlled
Randomization: To orforglipron 12 mg, 24 mg, or 36 mg daily oral, or matching placebo
Duration: 72 weeks treatment
N: 3,127 participants
Setting: Multinational

Population

Adults ≥18 years with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity, without type 2 diabetes
Adjunct to reduced-calorie diet and increased physical activity

Intervention

Orforglipron: First-in-class oral, non-peptide, small-molecule GLP-1 receptor agonist (Eli Lilly). Unlike Rybelsus (semaglutide SNAC-formulated oral peptide), orforglipron is not a peptide — it is a small molecule with intrinsic GLP-1R agonist activity and no food/water/timing restrictions.
Titrated over 12 weeks to target dose
Placebo: Matching oral tablet, identical schedule

Outcomes

Primary — Mean body weight change at week 72

Orforglipron 36 mg: -14.6% mean body weight reduction
Orforglipron 24 mg: -12.8%
Orforglipron 12 mg: -8.2%
Placebo: -2.0%
All doses superior to placebo (P<0.001)

Key Secondary

Proportion achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss — dose-dependent
Systolic BP reduction, waist circumference reduction, lipid improvement — all dose-responsive
HbA1c improvements in participants with elevated baseline

Key Findings

ATTAIN-1 establishes oral non-peptide GLP-1 agonism as a validated approach for chronic weight management. The 14.6% mean weight loss at the 36 mg dose is within the efficacy range of injectable semaglutide 2.4 mg (STEP 1: -14.9%) — a landmark result for an oral, non-peptide, unrestricted-administration agent.

Differentiation vs semaglutide oral (Rybelsus):

Orforglipron = small molecule, no food/water restrictions, manufacturing via chemical synthesis (scalable)
Semaglutide oral (Rybelsus) = peptide + SNAC absorption enhancer, strict 30-minute fast pre-dose + 120 mL water, peptide-manufacturing supply constraints

Clinical positioning:

Addresses the patient population that declines injectable therapy or cannot adhere to Rybelsus dosing restrictions
Manufacturing scalability may substantially expand access at scale
Cost positioning pending launch; expected to be cost-competitive with injectables at parity efficacy
Pill burden (daily) vs injectable convenience (weekly) — patient preference factor

Safety Profile

GI adverse events: Dose-dependent nausea (29-45% across doses), vomiting (11-24%), diarrhea (14-22%), constipation (13-19%)
Discontinuation due to GI AEs: 6-13% across doses vs 1% placebo
Hepatic enzymes: Minor transaminase elevations reported; most resolved with continued treatment
Pancreatitis, gallbladder events, thyroid C-cell signals: Incidence consistent with class expectations; black-box MTC warning anticipated at approval
No new unexpected safety signals beyond known GLP-1 class profile

Regulatory Status

FDA New Drug Application filed by Eli Lilly following ATTAIN-1 (2025-2026); approval status at time of reference — verify FDA.gov for current status.
Would be first oral non-peptide GLP-1 agonist approved for obesity if approved.

Limitations (Author-acknowledged)

Non-T2D population; companion trials (e.g., ATTAIN-T2D for diabetes) in parallel development
72-week duration; 2+ year durability being accumulated in extension studies
No head-to-head vs semaglutide or tirzepatide; cross-trial comparison only
Dose-response characterized, but optimal maintenance strategy not yet defined

Evidence Level

Level Ib (Oxford CEBM) — adequately-powered Phase 3 RCT with pre-specified primary endpoint and multiple active dose arms.

Linked Peptides

Orforglipron
Semaglutide (cross-trial / class comparator)

Related Studies

PMID-37385278 – OASIS 1 Oral Semaglutide for Obesity (oral peptide comparator)
PMID-33567185 – Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 cross-trial)
PMID-35658024 – SURMOUNT-1 Tirzepatide for Obesity (class cross-trial)

Orchestrator Notes

Funded by Eli Lilly.
Presented at ObesityWeek 2025 (November); simultaneous NEJM publication.
Represents paradigm shift: small-molecule GLP-1 agonism is now validated as a third pharmaceutical pathway (alongside peptide injectables and peptide oral formulations).
Orforglipron vault peptide note may not yet exist — requires creation with full profile upon sub-section completion.

DOI-10-1056-NEJMoa2511774 – ATTAIN-1 Orforglipron Obesity